Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peramivir in uncomplicated acute influenza
NCT00486980Phase 3
Key facts
- Status
- Withdrawn
- Modality
- Orthosteric Ligands
- Drugs
- peramivir
- Conditions
- influenza
01
Overview
Phase 3, randomised, double-blind trial of peramivir in influenza (3 arms), sponsored by BioCryst Pharmaceuticals, Inc. Status: withdrawn.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Peramivir 150mg
Single dose of Peramivir 150mg administered intramuscularly
Peramivir 300mg
Single dose of Peramivir 300mg administered intramuscularly
Placebo
Single dose of Placebo administered intramuscularly
03
Who it enrols
Adults with uncomplicated acute influenza, confirmed by Rapid Antigen Test or fever/symptoms, with symptom onset <= 48 hours. Excludes pregnant women, severe COPD/asthma, severe heart failure, renal impairment, active bacterial infection, immunocompromised status, active HCV, HIV with CD4 < 350, and recent use of other antivirals or live flu vaccine.
Beyond the preview
Go deeper on NCT00486980.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00486980.